Innotox (nivobotulinumtoxinA) / Medytox, AbbVie - LARVOL DELTA

NivobotulinumtoxinA in the Treatment of Lateral Canthal Lines Alone and With Concurrent Treatment of Glabellar Lines. (PubMed, Dermatol Surg) - "Liquid nivobotulinumtoxinA was effective and well-tolerated for treating moderate-to-severe LCL with/without GL."

Clinical • Journal • Aesthetic Medicine • Pain

Nanomaterials and security in occupational and forensic medicine: insights from nanotoxicology. (PubMed, Front Toxicol) - "Problems related to exposure to nanonenergetics can therefore potentially affect both exposed workers (both in the production and use phase) and the civilian population, if used in war scenarios, for example,. Starting from these assumptions, the INNOTOX research project aims to contribute to the in-depth study of the toxicity of nanonenergetics, through an integrated approach involving experts in occupational and forensic medicine, nanotoxicology and bioengineering."

Journal

NivobotulinumtoxinA in the Treatment of Glabellar Lines With or Without Concurrent Treatment of Lateral Canthal Lines in Two Phase 3 Clinical Trials. (PubMed, Aesthet Surg J) - "Liquid nivobotulinumtoxinA was effective and well tolerated for treating moderate-to-severe GL alone or with LCL."

Journal • P3 data • Aesthetic Medicine

MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL) (clinicaltrials.gov) - P3 | N=958 | Completed | Sponsor: Medy-Tox | Active, not recruiting ➔ Completed

Trial completion

MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL) (clinicaltrials.gov) - P3; N=800; Active, not recruiting; Sponsor: Allergan; Enrolling by invitation ➔ Active, not recruiting

Clinical • Enrollment closed